Eli Lilly Shares Surge on GLP‑1 Demand

Eli Lilly (LLY) shares jumped up to 7% on Wednesday, driven by stronger‑than‑expected demand for its GLP‑1 weight‑loss drugs.

GLP‑1 Demand Propels Stock Rally

■The company updated its 2026 revenue outlook to $85 billion‑$87 billion after the second‑quarter results.

■The prior projection capped at $85 billion.

■Adjusted earnings for the quarter beat Wall Street estimates.

■The stock has risen 40% since the end of April and is up 3% year‑to‑date.

New Formulation and Future Pipeline

■The FDA approved Foundayo, the pill version of its weight‑loss therapy, expanding the market for oral GLP‑1 agents.

■Lilly is preparing to file for FDA approval of next‑generation GLP‑1 candidate retatrutide in Q1 2027, with clinical data already in hand.

Investor Strategies and Market Implications

■Asset managers are increasing exposure to LLY as the GLP‑1 segment demonstrates robust growth.

■Analysts argue that the upward revision of the 2026 revenue ceiling warrants a fresh valuation of the stock.

Defne Aydın – Director of Geopolitical Risk and European Markets: Lilly’s GLP‑1‑centric growth model not only reshapes the U.S. landscape but also pressures European healthcare budgets. In the context of the ECB’s inflation outlook, rising health‑care expenditures could influence long‑term rate expectations and, consequently, equity returns.